



SUPRIYA LIFESCIENCE LIMITED
CIN No: L51900MH2008PLC180452

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: L51900MH2008PLC180452
Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2025

(₹ In million)

Sr.No.	Particulars	Quarter ended 30-06-2025	Quarter ended 31-03-2025	Quarter ended 30-06-2024	Year ended 31-03-2025
		Unaudited	Audited	Unaudited	Audited
	Income				
I	Revenue from Operations	1,450.74	1,841.09	1,606.26	6,964.85
II	Other Income	26.74	29.75	22.24	98.15
III	Total Income	1,477.48	1,870.84	1,628.50	7,063.00
2	Expenses				
	a) Cost of Materials Consumed	437.76	1,015.31	557.26	2,324.36
	b) Purchase of Stock in Trade	-	-	-	-
	c) Change in inventories of finished goods , work in progress & stock in trade.	-120.04	(467.05)	(71.29)	(212.59)
	d. Employee benefit expenses	226.88	209.77	200.84	805.19
	e. Finance Cost	5.12	4.17	3.35	16.86
	f. Depreciation & amortisation expense	64.51	60.81	46.56	204.44
	g. Other expenditure	389.13	407.21	294.03	1,439.93
IV	Total Expenses	1,003.36	1,230.22	1,030.76	4,578.19
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	474.12	640.61	597.74	2,484.80
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) before Tax (V-VI)	474.12	640.61	597.74	2,484.80
VIII	Tax Expense				
	a) Current Tax	105.35	127.72	146.67	566.57
	b) Deferred Tax	20.87	9.08	4.64	38.66
IX	Profit/(Loss) for the period from Continuing Operations (VII-VII)	347.90	503.82	446.44	1,879.58
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	347.90	503.82	446.44	1,879.58
XIV	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	-2.87	1.16	(0.74)	(1.67)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	0.72	(0.29)	0.19	0.42
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	345.75	504.69	445.88	1,878.33
XVI	Earnings per equity Share (for continuing operation):				
	(1) Basic (In ₹)	4.32	6.29	5.54	23.35
	(2) Diluted (In ₹)	4.32	6.29	5.54	23.35
XVII	Earnings per equity Share (for discontinued operation):				
	(1) Basic (In ₹)	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):				
	(1) Basic (In ₹)	4.32	6.29	5.54	23.35
	(2) Diluted (In ₹)	4.32	6.29	5.54	23.35

See accompanying notes to the financial statements:


Notes:-

1. The unaudited standalone financial results of the Company for the quarter ended June 30, 2025 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.
2. The above unaudited standalone financial results of the Company for the quarter ended June 30, 2025 have been reviewed by the Audit Committee on August 13, 2025 and thereafter approved by the Board of Directors at their meeting held on August 13, 2025.
3. The Company has adopted Ind AS 116 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.
4. The company does not have any subsidiary/associate/joint venture company as on June 30, 2025.
5. The figures of the previous periods have been regrouped wherever necessary to confirm to the current period presentation.

Place :- Mumbai
Date :- August 13, 2025



For Supriya Lifescience Limited


Dr. Satish Waman Wagh
Chairman and Whole time director.
DIN: 01456982